Volume 72 • November 2011 • Number 11
Original Research
1439 An Algorithm-Based Approach to First-Episode Schizophrenia: Response Rates Over 3 Prospective Antipsychotic Trials With a Retrospective Data Analysis
Ofer Agid, Tamara Arenovich, Gautam Sajeev, Robert B. Zipursky, Shitij Kapur, George Foussias, and Gary Remington
[Abstract] [Full Text]
1445 Predictors of Persistence of Comorbid Generalized Anxiety Disorder Among Veterans With Major Depressive Disorder
Dinesh Mittal, John C. Fortney, Jeffrey M. Pyne, and Julie L. Wetherell
[Abstract] [Full Text]
1452 Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I Disorder (Trial 144: A Randomized Controlled Study)
Richard H. Weisler, Willem A. Nolen, Anders Neijber, Åsa Hellqvist, and Björn Paulsson, for the Trial 144 Study Investigators
[Abstract] [Full Text] [eAppendix] [Clinical Points]
- In patients who respond to quetiapine, maintenance treatment with quetiapine (300-800 mg/d) significantly increases the time to recurrence of a mood event compared with placebo.
- Maintenance treatment with quetiapine increases the time to recurrence of both manic and depressive events and is effective regardless of the index mood event.
- Maintenance treatment with lithium is shown, for the first time, to increase the time to recurrence of a depressive as well as a manic event.
[Close]
1468 The Association Between Social Isolation and DSM-IV Mood, Anxiety, and Substance Use Disorders: Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions
Kee-Lee Chou, Kun Liang, and Jitender Sareen
[Abstract] [Full Text]
1487 The “Doses” of Initial, Untreated Hallucinations and Delusions: A Proof-of-Concept Study of Enhanced Predictors of First-Episode Symptomatology and Functioning Relative to Duration of Untreated Psychosis
Michael T. Compton, Tynessa L. Gordon, Paul S. Weiss, and Elaine F. Walker
[Abstract] [Full Text]
1494 Temporal Relationships Between Overweight and Obesity and DSM-IV Substance Use, Mood, and Anxiety Disorders: Results From a Prospective Study, the National Epidemiologic Survey on Alcohol and Related Conditions
Roger P. Pickering, Risë B. Goldstein, Deborah S. Hasin, Carlos Blanco, Sharon M. Smith, Boji Huang, Attila J. Pulay, W. June Ruan, Tulshi D. Saha, Frederick S. Stinson, Deborah A. Dawson, S. Patricia Chou, and Bridget F. Grant
[Abstract] [Full Text]
1515 Increased Systemic Cortisol Metabolism in Patients With Schizophrenia and Bipolar Disorder: A Mechanism for Increased Stress Vulnerability?
Nils Eiel Steen, Paal Methlie, Steinar Lorentzen, Sigrun Hope, Elizabeth A. Barrett, Sara Larsson, Erlend Mork, Bjørg Almås, Kristian Løvås, Ingrid Agartz, Ingrid Melle, Jens P. Berg, and Ole A. Andreassen
[Abstract] [Full Text]
1522 Self-Harm Subscale of the Schedule for Nonadaptive and Adaptive Personality (SNAP): Predicting Suicide Attempts Over 8 Years of Follow-Up
Shirley Yen, M. Tracie Shea, Zach Walsh, Maria O. Edelen, Christopher J. Hopwood, John C. Markowitz, Emily B. Ansell, Leslie C. Morey, Carlos M. Grilo, Charles A. Sanislow, Andrew E. Skodol, John G. Gunderson, Mary C. Zanarini, and Thomas H. McGlashan
[Abstract] [Full Text]
Case Report
1465 Cytochrome P450 2D6 Polymorphism and Its Impact on Decision-Making in Psychopharmacotherapy: Finding the Right Way in an Ultrarapid Metabolizing Patient
Michael Paulzen, Simone C. Tauber, André Kirner-Veselinovic, and Gerhard Gründer
[Abstract] [Full Text]
Review Article
1503 Meta-Analysis of Efficacy and Treatment-Emergent Suicidality in Adults by Psychiatric Indication and Age Subgroup Following Initiation of Paroxetine Therapy: A Complete Set of Randomized Placebo-Controlled Trials
David J. Carpenter, Regan Fong, John E. Kraus, John T. Davies, Christine Moore, and Michael E. Thase
[Abstract] [Full Text]
1478 Early and Delayed Onset of Response to Antidepressants in Individual Trajectories of Change During Treatment of Major Depression: A Secondary Analysis of Data From the Genome-Based Therapeutic Drugs for Depression (GENDEP) Study
Rudolf Uher, Ole Mors, Marcella Rietschel, Aleksandra Rajewska-Rager, Ana Petrovic, Astrid Zobel, Neven Henigsberg, Julien Mendlewicz, Katherine J. Aitchison, Anne Farmer, and Peter McGuffin
[Abstract] [Full Text] [Supplementary Material] [Clinical Points] [CME Activity]
- The time course of improvement after initiation of an antidepressant varies from patient to patient. While some patients experience rapid improvement in the first 2 to 3 weeks following initiation of an antidepressant, others start significantly improving only after a delay of 2 to 4 weeks. Early and delayed onsets of improvement are approximately equally common.
- If tolerated, an antidepressant should be continued for 6 to 8 weeks in adequate doses, even if there is no discernible therapeutic effect in the first 2 weeks of treatment. Patients who do not achieve improvement in the first 2 weeks of treatment still have a 40% to 50% chance of significant improvement if they persevere with treatment for 6 to 8 weeks.
- Six to eight weeks of treatment constitutes an adequate trial of an antidepressant. If significant improvement is not achieved after 6 to 8 weeks of treatment with adequate doses, the clinician should consider changing treatment.
[Close]
Focus on Women’s Mental Health
1529 Biopsychosocial Vulnerabilities in Women
Marlene P. Freeman
[Abstract] [Full Text]
1531 First-Onset Psychosis Occurring in the Postpartum Period: A Prospective Cohort Study
Veerle Bergink, Mijke P. Lambregtse-van den Berg, Kathelijne M. Koorengevel, Ralph Kupka, and Steven A. Kushner
[Abstract] [Full Text] [Clinical Points]
- First-onset postpartum psychosis has a distinct risk profile and phenomenology compared to postpartum psychosis in patients with bipolar disorder.
- Depressive symptoms were associated with a later onset and longer duration of episode.
- Treatment with the combination of lithium plus an antipsychotic led to high rates of remission.
[Close]
1538 Prevalence of Mood Disorders and Service Use Among US Mothers by Race and Ethnicity: Results From the National Survey of American Life
Rhonda C. Boyd, Sean Joe, Lynn Michalopoulos, Erica Davis, and James S. Jackson
[Abstract] [Full Text] [Clinical Points]
- Mothers are a group that may be at increased risk for mood disorders.
- It is important to assess for risk factors, identify mood disorders, and adequately treat these disorders in mothers.
- Black mothers with mood disorders are likely to underutilize treatment.
[Close]
1546 Decreased Nocturnal Oxytocin Levels in Anorexia Nervosa Are Associated With Low Bone Mineral Density and Fat Mass
Elizabeth A. Lawson, Daniel A. Donoho, Justine I. Blum, Erinne M. Meenaghan, Madhusmita Misra, David B. Herzog, Patrick M. Sluss, Karen K. Miller, and Anne Klibanski
[Abstract] [Full Text] [Clinical Points]
- Oxytocin is a peptide hormone involved in appetite as well as bone metabolism.
- Anorexia nervosa is characterized by restrictive eating, extremely low weight, and severe bone loss.
- Nocturnal oxytocin levels are low in women with anorexia nervosa and are positively associated with bone mineral density, suggesting that oxytocin deficiency may contribute to bone loss in this disorder.
[Close]
1552 Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Trial
Judith Usall, Elena Huerta-Ramos, Raquel Iniesta, Jesús Cobo, Susana Araya, Mercedes Roca, Antoni Serrano-Blanco, Fernando Teba, and Susana Ochoa
[Abstract] [Full Text] [Clinical Points]
- Drugs with estrogen activity in the brain seem to improve the outcome of subjects with schizophrenia.
- Use of raloxifene as an adjuvant treatment in postmenopausal women with schizophrenia is very promising.
[Close]
Letters to the Editor
1558 Can Pindolol Really Enhance Antidepressant Effect?
Takeshi Terao
[Purchase] [Full Text]
• Reply by Maria J. Portella, Javier Ballesteros, Francesc Artigas, and Víctor Pérez
[Purchase] [Full Text]
1558 Odd Odds
Chittaranjan Andrade
[Purchase] [Full Text]
• Reply by David J. Carpenter, Regan Fong, John E. Kraus, John T. Davies, Christine Moore, and Michael E. Thase
[Purchase] [Full Text]
Book Reviews
1560 Mental Health Care in the College Community
Mary W. Roberts
[Purchase] [Full Text]
1560 Principles of Social Psychiatry, 2nd ed.
Susan L. Padrino
[Purchase] [Full Text]
1561 Psychodynamic Psychotherapy for Personality Disorders: A Clinical Handbook
David I. Joseph
[Purchase] [Full Text]
Psychiatrist.com Exclusives
Focus on Women’s Mental Health
e1563 Depression in Women: Windows of Vulnerability and New Insights Into the Link Between Estrogen and Serotonin [Commentary]
Sonali Lokuge, Benicio N. Frey, Jane A. Foster, Claudio N. Soares, and Meir Steiner
[Abstract] [Full Text] [Clinical Points]
- Women are at higher risk for developing depression compared to men, and such increased risk appears to be associated with reproductive “windows of vulnerability.”
- The association between reproductive milestones and depression in women suggests a contributing role of sex hormones (ie, estrogen) to mood regulation.
- Animal data and clinical studies support the notion that estrogen has important modulatory effects on serotonin activity.
[Close]
Online Activities
e34 2011 ICBD Conference Coverage: Practical Applications of New Research in Bipolar Disorder [CME]
Paul King
[Abstract]
e35 Implementing Guideline-Based Strategies to Avoid Relapse and Recurrence in Depression [CME]
Roger S. McIntyre
[Abstract]
Information for Authors
see www.psychiatrist.com/author.htm
